Piramal Pharma Limited (PPLPHARMA.NS)
INR 211.04
(-0.0%)
INR 211.04
(-0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.31 Billion INR | 3120.42% |
| 2022 | 141.5 Million INR | -97.47% |
| 2021 | 5.6 Billion INR | 1.78% |
| 2020 | 5.5 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.49 Billion INR | 649.2% |
| 2024 Q1 | 199.4 Million INR | -94.03% |
| 2023 Q1 | -412.9 Million INR | -120.73% |
| 2023 FY | 4.55 Billion INR | 3120.42% |
| 2023 Q4 | 3.33 Billion INR | 111.92% |
| 2023 Q3 | 1.57 Billion INR | 5.41% |
| 2023 Q2 | 1.49 Billion INR | 461.9% |
| 2022 Q1 | -528.4 Million INR | -126.2% |
| 2022 FY | 141.5 Million INR | -97.47% |
| 2022 Q4 | 1.99 Billion INR | 847.83% |
| 2022 Q3 | 210.1 Million INR | -67.01% |
| 2022 Q2 | 636.8 Million INR | 220.51% |
| 2021 Q1 | 446.7 Million INR | 0.0% |
| 2021 FY | 5.6 Billion INR | 1.78% |
| 2021 Q4 | 2.01 Billion INR | -18.74% |
| 2021 Q3 | 2.48 Billion INR | 324.24% |
| 2021 Q2 | 585 Million INR | 30.96% |
| 2020 FY | 5.5 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biocon Limited | 50.83 Billion INR | 91.511% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | -27.96% |
| Concord Biotech Limited | 6.26 Billion INR | 31.089% |
| Dishman Carbogen Amcis Limited | -413 Million INR | 1144.818% |
| Jubilant Ingrevia Limited | 2.93 Billion INR | -46.775% |
| Lyka Labs Limited | 29.13 Million INR | -14713.251% |
| Panacea Biotec Limited | - INR | -Infinity% |
| SMS Lifesciences India Limited | 359.47 Million INR | -1100.399% |
| Supriya Lifescience Limited | 1.57 Billion INR | -174.559% |
| Syngene International Limited | 6.46 Billion INR | 33.285% |
| TAKE Solutions Limited | -213.49 Million INR | 2121.219% |
| Zota Health Care Limited | -129.79 Million INR | 3424.525% |